di Iasio MG - Search Results

1

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

Secchiero P, di Iasio MG, Gonelli A, Zauli G. Secchiero P, et al. Among authors: di iasio mg. Curr Pharm Des. 2008;14(21):2100-10. doi: 10.2174/138161208785294663. Curr Pharm Des. 2008. PMID: 18691119 Review.

2

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P. Zauli G, et al. Among authors: di iasio mg. Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689683 Free PMC article. Clinical Trial.

3

Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages.

Secchiero P, Rimondi E, di Iasio MG, Voltan R, Gonelli A, Zauli G. Secchiero P, et al. Among authors: di iasio mg. J Cell Physiol. 2012 May;227(5):1829-37. doi: 10.1002/jcp.22910. J Cell Physiol. 2012. PMID: 21732354

4

C-Reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway.

Secchiero P, Rimondi E, di Iasio MG, Agnoletto C, Melloni E, Volpi I, Zauli G. Secchiero P, et al. Among authors: di iasio mg. Clin Cancer Res. 2013 Apr 15;19(8):1949-59. doi: 10.1158/1078-0432.CCR-12-3027. Epub 2013 Mar 6. Clin Cancer Res. 2013. PMID: 23468057 Free article.

5

The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.

di Iasio MG, Zauli G. di Iasio MG, et al. Invest New Drugs. 2013 Apr;31(2):458-60. doi: 10.1007/s10637-012-9882-y. Epub 2012 Oct 2. Invest New Drugs. 2013. PMID: 23054209

6

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.

di Iasio MG, Norcio A, Melloni E, Zauli G. di Iasio MG, et al. Invest New Drugs. 2012 Dec;30(6):2403-6. doi: 10.1007/s10637-011-9786-2. Epub 2012 Jan 13. Invest New Drugs. 2012. PMID: 22238073

7

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G. Voltan R, et al. Among authors: di iasio mg. Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13. Clin Cancer Res. 2011. PMID: 21753157 Free article.

8

Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.

Corallini F, Celeghini C, Rimondi E, di Iasio MG, Gonelli A, Secchiero P, Zauli G. Corallini F, et al. Among authors: di iasio mg. J Cell Physiol. 2011 Sep;226(9):2279-86. doi: 10.1002/jcp.22564. J Cell Physiol. 2011. PMID: 21660951

9

Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples.

di Iasio MG, Addobbati R, Radillo O, Voltan R. di Iasio MG, et al. Invest New Drugs. 2012 Aug;30(4):1761-5. doi: 10.1007/s10637-011-9695-4. Epub 2011 May 31. Invest New Drugs. 2012. PMID: 21626114 No abstract available.

10

The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.

Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G. Secchiero P, et al. Among authors: di iasio mg. Clin Cancer Res. 2010 Mar 15;16(6):1824-33. doi: 10.1158/1078-0432.CCR-09-3031. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results